San Francisco, CA, United States of America

Isaac J Rondon

This inventor holds 15 USPTO granted patents and 9 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Pfizer Corporation, University of California, Dyax Corporation. Active years: 2004-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Isaac J Rondon. Retrieved from https://idiyas.com/inventor/isaac-j-rondon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 9)

% Patents Active = 86.7

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 18(Granted Patents)

Location History:

Boston, MA (US) (2004 - 2005)
Berkeley, CA (US) (2013)
San Francisco, CA (US) (2008 - 2022)

Company Filing History:

University of California

Leland Stanford Junior University

patents

5. 2 out of 10

The Cbr Institute for Biomedical Research, Inc.

Beth Israel Deaconess Medical Center, Inc.

where one patent can have more than one assignee

Years Active: 2004-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12595301 - ANTI-IL-2 ANTIBODIES AND COMPOSITIONS AND USES THEREOF (2026-04-07),

2. 12371507 - CDCP1 antibodies and antibody drug conjugates (2025-07-29),

3. 12371499 - Method of treating cancer using anti-AV8 antibodies (2025-07-29),

4. 11459385 - Anti-IL-2 antibodies and compositions and uses thereof (2022-10-04),

5. 11359024 - Anti-AVB8 antibodies and compositions and uses thereof (2022-06-14),

6. 11066481 - Antibodies to coagulation factor XIa and uses thereof (2021-07-20),

7. 10738113 - Anti-IL-2 antibodies and compositions and uses thereof (2020-08-11),

8. 10138298 - Anti-IL-2 antibodies and compositions and uses thereof (2018-11-27),

9. 8546308 - Triple tag sequences and methods of use thereof (2013-10-01),

10. 8546307 - Triple tag sequence and methods of use thereof (2013-10-01),

11. 8247185 - Conformation specific antibodies (2012-08-21),

12. 7927591 - Conformation specific antibodies (2011-04-19),

13. 7438890 - Binding peptides for carcinoembryonic antigen (CEA) (2008-10-21),

14. 6919424 - Binding peptides for carcinoembryonic antigen (CEA) (2005-07-19),

15. 6774209 - Binding peptides for carcinoembryonic antigen (CEA) (2004-08-10),

Title: The Innovative Contributions of Isaac J Rondon

Introduction

Isaac J Rondon is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 14 patents to his name, Rondon's work has the potential to impact cancer treatment and other medical applications.

Latest Patents

Among his latest patents, Rondon has developed materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy. This innovative approach aims to provide effective treatment options for cancer patients. Additionally, he has invented a method of treating cancer using anti-AV8 antibodies, which specifically bind to αvβ8 integrin. This invention includes various uses and associated methods for utilizing these antibodies in therapeutic settings.

Career Highlights

Throughout his career, Rondon has worked with notable organizations such as Pfizer Corporation and the University of California. His experience in these esteemed institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Rondon has collaborated with talented individuals, including Lauren K Ely and Natasha K Crellin. These partnerships have further enhanced his research and development efforts in the biotechnology sector.

Conclusion

Isaac J Rondon's innovative work in the field of biotechnology, particularly in antibody development, showcases his dedication to advancing medical science. His contributions have the potential to lead to significant improvements in cancer treatment and patient care.

Profile summary based on public USPTO records.